NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis $3.74 -0.08 (-1.97%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OmniAb Stock (NASDAQ:OABI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OmniAb alerts:Sign Up Key Stats Today's Range$3.73▼$3.8550-Day Range$3.17▼$4.0652-Week Range$3.10▼$6.55Volume78,979 shsAverage Volume479,999 shsMarket Capitalization$527.46 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewOmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.Read More… OmniAb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreOABI MarketRank™: OmniAb scored higher than 34% of companies evaluated by MarketBeat, and ranked 787th out of 959 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmniAb has received no research coverage in the past 90 days.Read more about OmniAb's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OmniAb's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.08% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently increased by 1.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.08% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently increased by 1.54%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for OmniAb this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added OmniAb to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $268,356.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OmniAb's insider trading history. Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Stock News HeadlinesOmniAb, Inc. (NASDAQ:OABI) CFO Sells $50,304.24 in StockJanuary 23, 2025 | insidertrades.comOmniAb (OABI) Gets a Buy from RBC CapitalFebruary 6, 2025 | markets.businessinsider.comForget morning trades: Here’s when real money movesWhen 12pm Eastern rolls around… Something really special happens. It’s the first hour of the day that the overseas markets are closed… And it’s the FIRST time that we can see Wall Street trading freely on their own – without the noise from the international markets… That’s why we see so many opportunities during the Genesis Hour. And anyone who can spot stocks breaking out during the 12 pm Genesis Hour can then jump in ahead of what could be the next big move… Intrigued? You should be! Because it’s one of the most exciting, little-known revelations I’ve uncovered in my 40+ years trading the markets. If you’d like to join him for a deeper dive… February 18, 2025 | Diversified Trading Institute (Ad)Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law FirmJanuary 31, 2025 | prnewswire.comOmniAb Insider Ups Holding During YearJanuary 27, 2025 | finance.yahoo.comOABI stock touches 52-week low at $3.16 amid market challengesJanuary 24, 2025 | msn.comOmniab CEO Matthew Foehr sells $135,467 in stockJanuary 22, 2025 | msn.comOmniab CFO Kurt Gustafson sells shares worth $50,304January 22, 2025 | msn.comSee More Headlines OABI Stock Analysis - Frequently Asked Questions How have OABI shares performed this year? OmniAb's stock was trading at $3.54 on January 1st, 2025. Since then, OABI shares have increased by 7.6% and is now trading at $3.81. View the best growth stocks for 2025 here. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business earned $7.61 million during the quarter, compared to analysts' expectations of $6.52 million. OmniAb had a negative trailing twelve-month return on equity of 20.97% and a negative net margin of 308.78%. Who are OmniAb's major shareholders? OmniAb's top institutional investors include Janus Henderson Group PLC (5.64%), Vanguard Group Inc. (3.58%), Dimensional Fund Advisors LP (2.14%) and Chicago Capital LLC (2.11%). Insiders that own company stock include Charles S Berkman, Kurt A Gustafson and Jennifer R Cochran. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OmniAb own? Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings8/08/2024Today2/18/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+136.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,620,000.00 Net Margins-308.78% Pretax Margin-373.44% Return on Equity-20.97% Return on Assets-18.05% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual Sales$34.16 million Price / Sales15.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book1.42Miscellaneous Outstanding Shares141,220,000Free Float129,071,000Market Cap$538.05 million OptionableOptionable Beta-0.12 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:OABI) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OmniAb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.